NCT04701619View on ClinicalTrials.gov

Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)

NANot yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 15, 2026

Primary Completion Date

October 15, 2027

Study Completion Date

May 15, 2028

Conditions
StrokeIschemic Stroke
Interventions
OTHER

Immuno-inflammatory profile description in patients with ischemic stroke

Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK